Business Context and Reporting Period
Company: Molecular Partners AG
Filing Type: Annual Report on Form 20-F
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Molecular Partners is a clinical-stage biotechnology company pioneering the design and development of DARPin (Designed Ankyrin Repeat Protein) therapeutics, primarily focused on oncology. The company has no approved products and generates revenue solely through collaboration agreements and milestone payments. Key programs include MP0712 (Radio-DARPin for SCLC), MP0533 (T-cell engager for AML), and MP0317 (CD40 agonist for solid tumors).
Key Financial Metrics
| Metric (CHF thousands) | 2025 | 2024 | 2023 |
|---|---|---|---|
| Total Revenues | 0 | 4,970 | 7,038 |
| Operating Expenses | (58,124) | (66,187) | (68,146) |
| Net Result (Loss) | (61,651) | (54,043) | (61,984) |
| Cash and Cash Equivalents | 82,653 | 63,874 | 67,309 |
| Short-term Time Deposits | 10,405 | 85,565 | 119,580 |
| Total Liquidity (Cash + Deposits) | 93,058 | 149,439 | 186,889 |
| Net Cash Used in Operating Activities | (51,257) | (59,248) | (59,005) |
| Cumulative Losses | (311,753) | (246,293) | (191,755) |
Note: The filing does not provide specific margin percentages as the company has no product revenue. All figures are in Swiss Francs (CHF).
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped to zero in 2025 compared to CHF 4.97 million in 2024. This is due to the conclusion of revenue recognition under the Novartis Radioligand Agreement, which ended in Q3 2024.
- Expense Reduction: Total operating expenses decreased by approximately CHF 8.1 million (12%) to CHF 58.1 million, driven by reduced costs for programs MP0533 and MP0317 and lower SG&A costs.
- Liquidity Decrease: Total cash and short-term time deposits decreased by approximately CHF 56.4 million (38%) to CHF 93.1 million, primarily due to the drawdown of short-term time deposits and operating cash burn.
- Restructuring Costs: The company incurred CHF 2.7 million in restructuring expenses in 2025 following a June 2025 initiative that affected 34 employees, primarily in R&D. No such costs were recorded in 2024.
- Financial Income/Expense: Net financial result shifted from a gain of CHF 7.2 million in 2024 to a loss of CHF 3.5 million in 2025, driven by lower interest income and foreign exchange losses.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Cash Runway: Management expects existing cash and short-term time deposits (CHF 93.1 million as of Dec 31, 2025) to fund operating expenses and capital expenditures through 2028.
- Strategic Focus: Priority is placed on advancing MP0712 (Phase 1/2a trial commenced Dec 2025), MP0533 (dose escalation ongoing), and MP0317 (Phase 2 trial initiated Jan 2026).
- Collaborations: Expanded collaboration with Orano Med to co-develop up to ten 212Pb-based Radio-DARPin programs. A new development agreement with Eckert & Ziegler was signed in Dec 2025 for targeted alpha radio-therapeutics.
Key Risks and Contingencies:
- Need for Capital: The company has incurred significant losses since inception and expects to continue doing so. Failure to raise additional capital could force delays or termination of product development.
- Clinical Development Risks: All product candidates are in preclinical or clinical stages. Delays, negative trial results, or regulatory rejections (particularly for MP0533, MP0317, and MP0712) could materially harm the business.
- Intellectual Property: Base patents for the DARPin technology have expired. The company relies on newer patents and trade secrets, which may be challenged or invalidated.
- Third-Party Dependence: The company relies entirely on third-party contract manufacturers (CMOs) and collaborators (e.g., Orano Med, Novartis) for development and commercialization.
- PFIC Status: The company believes it was a Passive Foreign Investment Company (PFIC) for the 2025 tax year, which may have adverse tax consequences for U.S. holders.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the CHF 93.1 million liquidity position against the projected burn rate to confirm the 2028 runway estimate.
- Revenue Pipeline: Assess the likelihood and timing of future milestone payments from the Orano Med collaboration and other partners to replace the lost Novartis revenue.
- Clinical Trial Progress: Monitor upcoming data readouts for MP0712 (expected 2026) and MP0533 (update expected H1 2026) for safety and efficacy signals.
- Restructuring Impact: Evaluate the long-term impact of the 34-person headcount reduction on the company's ability to execute its clinical development plans.
- Patent Portfolio: Review the status of pending patent applications for Switch-DARPins and Radio-DARPins to ensure adequate IP protection post-expiration of base patents.